|Bid||10.92 x 900|
|Ask||11.00 x 800|
|Day's range||10.93 - 11.64|
|52-week range||10.83 - 29.65|
|Beta (5Y monthly)||1.08|
|PE ratio (TTM)||22.94|
|Earnings date||23 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||26.25|
Horizon (HZNP) enrolls the first patient in a phase IIb study evaluating HZN-825 for the treatment of idiopathic pulmonary fibrosis.
If you want to know who really controls Cara Therapeutics, Inc. ( NASDAQ:CARA ), then you'll have to look at the makeup...
Please be advised that this call is being recorded at Cara's request. This is Will Gramig with Stern Investor Relations, and welcome to Cara Therapeutics' third quarter 2021 financial results and update conference call. Before we begin, let me remind you that statements made on today's call regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.